Dobutamine NDC 51662-1337

NDC codes

FDA NDC Directory

Product NDC (as listed)51662-1337Labeler and product segments. Claims need a package NDC.

Product NDC at billing width51662-1337Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
51662-1337-1	51662133701	20 mL in 1 VIAL, SINGLE-DOSE (51662-1337-1)Marketed from Nov 26, 2018
51662-1337-3	51662133703	10 POUCH in 1 CASE (51662-1337-3) / 1 VIAL, SINGLE-DOSE in 1 POUCH (51662-1337-2) / 20 mL in 1 VIAL, SINGLE-DOSEMarketed from Jun 12, 2022

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Dobutamine
Generic name (nonproprietary): dobutamine
Active ingredients: Dobutamine hydrochloride — 12.5 mg/mL
Dosage form: Injection, Solution, Concentrate
Route: Intravenous
Labeler: HF Acquisition Co LLC, DBA HealthFirst
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 074086
Marketing start: Nov 26, 2018
Listing expires: Dec 31, 2026
Other FDA classes: Adrenergic beta-Agonists (Mechanism)
Identifiers: Product ID 51662-1337_11c1b110-433c-7887-e063-6294a90a1e52SPL ID 11c1b110-433c-7887-e063-6294a90a1e52SPL set ID 7b9ea626-7072-2e77-e053-2a91aa0a9215RxCUI 1812168UNII 0WR771DJXV
Pharmacologic class: beta-Adrenergic Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N451662133701 followed by a unit qualifier and the quantity

Package 51662-1337-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Feb 19, 2024.

Indications (excerpt from the label)

INDICATIONS & USAGE Dobutamine Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 074086

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 074086
Product	Strength	Form · route	Labeler	Product NDC
Dobutamine	Dobutamine hydrochloride 12.5 mg/mL	Injection, Solution, ConcentrateIntravenous	Hospira, Inc.	0409-2344
Dobutamine	Dobutamine hydrochloride 12.5 mg/mL	Injection, Solution, ConcentrateIntravenous	Hospira, Inc.	0409-2344